Mr. Cramer has more than 15 years of industry experience in nonclinical development and safety evaluation of small molecules and biologics from early discovery through commercialization. His experience as a toxicologist includes strategic, technical, and regulatory product support, and authoring of numerous IND/CTAs and NDA/BLA/MAAs in multiple disease areas. Prior to joining DRA, Mr. Cramer was Senior Director of Nonclinical Development at Prothelia, Inc. and Senior Director of Toxicology at Dyne Pharmaceuticals. He holds an M.S. in Toxicology from Northeastern University, and a B.S. in Biology from Syracuse University.